Stocksigma LogoStocksigma Logo

Panacea Biotec Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)

■ Revenue: 18,967 (+34.4% YoY | -5.0% QoQ) ■ EBITDA: 1,550 (Loss to Profit YoY | +173.4% QoQ) ■ EBITDA Margin (%): 8.2 (Loss to Profit YoY | +533 bps QoQ)

Panacea Biotec Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)

Panacea Biotec Ltd · Outcome · 15 Nov 2026, 1:55 am

Panacea Biotec Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 18,967 (+34.4% YoY | -5.0% QoQ) ■ EBITDA: 1,550 (Loss to Profit YoY | +173.4% QoQ) ■ EBITDA Margin (%): 8.2 (Loss to Profit YoY | +533 bps QoQ) ■ PAT: 1,161 (Loss to Profit YoY | +404.8% QoQ) ■ EPS (INR): 1.90 (Loss to Profit YoY | +400.0% QoQ) Panacea Biotec Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) Segmental Performance Vaccines ■ Revenue: 12,422 (+36.8% YoY | -7.8% QoQ) ■ EBIT: 1,685 (Loss to Profit YoY | +125.6% QoQ) ■ EBIT Margin (%): 13.6 (Loss to Profit YoY | +802 bps QoQ) Formulations ■ Revenue: 6,545 (+30.1% YoY | +0.8% QoQ) ■ EBIT: 14.0 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBIT Margin (%): 0.2 (Loss to Profit YoY | Loss to Profit QoQ)

Original exchange filing (PDF)

More announcements from Panacea Biotec Ltd

All Panacea Biotec Ltd announcements